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ABSTRACT
Introduction: Glycated haemoglobin A1c
(HbA1c) is the established standard measure-
ment for assessment of glycaemic control in
people with diabetes. Here we report on a meta-
analysis of real-world observational studies on
the impact of flash continuous glucose moni-
toring on glycaemic control as measured by
HbA1c.
Methods: A total of 271 studies were identified
in our search, of which 29 contained data
reporting changes in HbA1c over periods from 1
to 24 months that could be used in a statistical
analysis. Our meta-analysis focuses on observed
change in HbA1c at either 2, 3 or 4 months, in
adult or paediatric subjects, as well as a longi-
tudinal analysis up to 12 months in adult sub-
jects. These data were drawn from 25 of the
studies identified in our initial search. These
reported HbA1c data up to 12 months in a total
of 1723 participants with type 1 diabetes (T1D)
or type 2 diabetes (T2D) using the FreeStyle
Libre flash glucose monitoring system.
Results: Overall mean change in laboratory
HbA1c across study subjects at 2–4 months was
- 0.55% (95% CI - 0.70, - 0.39). Amongst the
1023 adults, mean change in HbA1c was
- 0.56% (95% CI - 0.76, - 0.36); for the 447
children and adolescents, mean change in
HbA1c was - 0.54% (95% CI - 0.84, - 0.23).
Based on regression analysis, the degree of
change in HbA1c correlated with the initial
HbA1c of the study population. A longitudinal
analysis in adult subjects (n = 1276) shows that
HbA1c fell within the first 2 months and chan-
ges were sustained up to 12 months. No signif-
icant differences were detected between T1D
and T2D.
Conclusion: The meta-analysis reported here
confirms that starting the FreeStyle Libre system
as part of diabetes care results in a significant
and sustained reduction in HbA1c for adults
and children with T1D and for adults with T2D.
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Key Summary Points
Starting the FreeStyle Libre system as part
of daily diabetes care results in a
significant reduction in HbA1c for adults
and children with T1D and for adults with
T2D.
Adult subjects with T1D or T2D
demonstrated a rapid and sustained
reduction in HbA1c.
The degree of change in HbA1c is
predicted by the HbA1c at baseline prior
to starting the FreeStyle Libre system.
INTRODUCTION
The evidence that good glucose control, as
measured by reduced glycated haemoglobin
A1c (HbA1c), is strongly associated with better
outcomes for patients with type 1 diabetes
(T1D) or with type 2 diabetes (T2D) is widely
accepted. Both the Diabetes Control and Com-
plications Trial (DCCT) Research Group [1] and
the UK Prospective Diabetes Study (UKPDS)
Group [2, 3] demonstrated that a lowering of
HbA1c is associated with clinically significant
reductions in microvascular complications and
long-term macrovascular disease.
Randomized clinical trials (RCTs) indicate
that, in comparison to self-monitoring blood
glucose (SMBG) testing, several continuous
glucose monitoring (CGM) systems are shown
to reduce laboratory-measured HbA1c, as well as
measures of hypoglycaemia and glycaemic
variability in people with diabetes [4–8]. How-
ever, in studies using the FreeStyle Libre flash
glucose monitoring system to date, only the
single-arm SELFY study showed a significant
reduction in HbA1c (- 0.4%, p\0.001) [9].
Two RCTs, IMPACT and REPLACE, showed no
change in HbA1c over 26 weeks comparing the
FreeStyle Libre system with SMBG in the total
study population [10, 11]. The IMPACT study
was designed to show a reduction in
hypoglycaemia rather than HbA1c, with the
mean HbA1c at baseline already at 6.7%. In
REPLACE, a significant change in HbA1c was
reported in a pre-specified subgroup of subjects
under 65 years old. In this subgroup, users of
the FreeStyle Libre system experienced a statis-
tically significant HbA1c reduction of - 0.33%
versus SMBG [11]. Importantly though, the
FreeStyle Libre system was shown in both
IMPACT and REPLACE to reduce measures of
hypoglycaemia and glycaemic variability in
adults with T1D or T2D on insulin [10, 11].
In addition to RCTs, a growing number of
real-world observational studies have reported
outcomes for people with T1D or T2D using the
FreeStyle Libre system, including a change in
laboratory-measured HbA1c levels. Given the
importance of HbA1c as a measure of glycaemic
control in patients with diabetes, we aimed to
examine the changes in HbA1c revealed in
these real-world studies.
In a rapidly moving clinical landscape in
which treatment decisions must be made in as
timely a fashion as possible, the increasing
importance of observational studies within
meta-analyses is recognised. Although a known
limitation of observational studies is their sus-
ceptibility to selection bias and reporting bias,
guidelines have now been established to address
and manage these issues and to help standardise
reporting within meta-analyses [12, 13]. The
most apt in the context of the current analysis
are the Meta-analysis Of Observational Studies
in Epidemiology (MOOSE) [12].
The aims of this meta-analysis were three-
fold: (1) to establish whether use of the Free-
Style Libre flash glucose monitoring system
favours a reduction in HbA1c when used by
people with T1D or T2D as a replacement for
SMBG in their standard care; (2) to identify
whether changes in final HbA1c reported in
RCTs or real-world observational studies exhibit
a dependency on mean initial HbA1c amongst
the study population using the FreeStyle Libre
system; (3) to identify whether longitudinal
changes in HbA1c reported in RCTs or real-
world observational studies using the FreeStyle
Libre system in adult subjects differ on the basis
of length of study and type of diabetes (T1D vs
T2D).
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METHODS
Search Strategy and Study Selection
A search was conducted across the following
abstracting and indexing databases: Allied and
Complementary MedicineTM, Analytical
Abstracts, BIOSIS Previews, Embase, EMCare,
International Pharmaceutical Abstracts, MED-
LINE, ToxFile. The searched string of terms
and the subsequent selection flow diagram are
detailed in Fig. 1. Additionally, two studies were
identified through conference abstracts.
A total of 29 studies were identified that
reported longitudinal laboratory HbA1c data in
participants with T1D or T2D using the Free-
Style Libre system over periods from 1 to
24 months (Table 1). Our meta-analysis focuses
on observed change in HbA1c at either 2, 3 or
4 months, as well as a longitudinal analysis up
to 12 months. These data were drawn from 25
of the studies identified in our initial search, as
indicated in Table 1. This included participants
with T1D (n = 1496) or T2D (n = 227). Studies
were included if data were reported in a manner
that could be used in a statistical meta-analysis.
Data included observations on children, ado-
lescents and adults with T1D or T2D (Table 1).
For the RCTs within this analysis set, the
within-intervention arm results have been
included, not the between-arm results reported
previously. All RCTs and observational studies
are reported here as absolute change from
baseline to ensure a consistent approach and to
reflect the real-world patient-centred outcome,
Fig. 1 Search strategy and study selection
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Table 1 Summary of studies with longitudinal data using flash glucose monitoring included in the meta-analysis
Study Outcome
time
points
(month)
Adults/
children
Type of
diabetes
Number
of
subjects
Initial
HbA1c
(%)
Change
in
HbA1c
(%)
SE
change
in
HbA1c
(%)
Data used
in analysis
in Figs. 3
and 4
Data
used in
analysis
in Fig. 5
Gibb 2018
[14]
10 Adults 1 204 Unknown - 0.27 0.082
Bolinder 2016
[10]
3 Adults 1 119 6.79 0.06 0.046 4 4
6 Adults 1 119 6.79 0.16 0.047 4
Xatzipsalti
2017 [15]
3 Children 1 51 7.06 - 1.00 0.269 4
Reddy 2017
[16]
2 Adults 1 20 7.20 - 0.35 0.143 4 4
Moreno-
Fernandez
2018 [17]
6 Adults 1 18 7.40 - 0.40 0.120 4
Helm 2016
[18]
2 Children 1 31 7.42 - 0.22 0.111 4
Messaaoui
2018 [19]
12 Children 1 278 7.6 0.10 0.054
Wijnands 2017
[20]
3 Children 1 72 7.70 - 0.20 0.100 4
McKnight
2017 [21]
Unknown Adults 1 169 7.73 - 0.23 0.056
Campbell 2017
[9]
2 Children 1 75 7.90 - 0.40 0.069 4
Walton-
Betancourth
2017 [22]
3 Children 1 47 7.93 - 0.09 0.079 4
Dover 2016
[23]
4 Adults 1 25 8.00 - 0.48 0.128 4 4
Bacon 2017
[24]
3 Adults 1 58 8.10 - 0.55 0.230 4 4
Dørflinger
2018 [25]
3 Adults 1 209 8.10 - 0.46 0.098 4 4
6 Adults 1 146 8.10 - 0.64 0.190 4
9 Adults 1 75 8.10 - 0.37 0.107 4
12 Adults 1 25 8.10 - 1.01 0.305 4
86 Diabetes Ther (2020) 11:83–95
Table 1 continued
Study Outcome
time
points
(month)
Adults/
children
Type of
diabetes
Number
of
subjects
Initial
HbA1c
(%)
Change
in
HbA1c
(%)
SE
change
in
HbA1c
(%)
Data used
in analysis
in Figs. 3
and 4
Data
used in
analysis
in Fig. 5
Pintus 2017
[26]
3 Children 1 52 8.23 - 0.73 0.268 4
Karlsson 2017
[27]
12 Adults 1 164 8.45 - 0.49 0.124 4
Al Hayek 2017
[28]
3 Children 1 47 8.50 - 0.66 0.238 4
Paris 2017 [29] 3 Adults 1 107 8.51 - 0.67 0.109 4 4
6 Adults 1 109 8.51 - 0.68 0.117 4
9 Adults 1 104 8.51 - 0.48 0.118 4
12 Adults 1 102 8.51 - 0.46 0.123 4
Abdalaziz 2018
[30]
6 Adults 1 40 8.56 - 0.55 0.174 4
12 Adults 1 40 8.56 - 0.64 0.166 4
Haak 2017
[11]
3 Adults 2 149 8.65 - 0.44 0.080 4 4
6 Adults 2 149 8.65 - 0.27 0.083 4
Yaron 2019
[31]
2 Adults 2 53 8.68 - 0.82 0.116 4 4
Weiss 2018
[32]
Unknown Adults Mix* 22 8.70 - 1.00 0.262
Lo¨ndahl 2017
[33]
3 Adults 1 226 8.72 - 0.65 0.050 4 4
12 Adults 1 226 8.72 - 0.74 0.063 4
Landau 2018
[34]
3 Children 1 59 8.86 - 0.81 0.031 4
Ish-Shalom
2016 [35]
1 Adults 1 and 2 6 and 25 8.90 - 0.80 0.178 4
2 Adults 1 and 2 6 and 25 8.90 - 1.33 0.290 4
3 Adults 1 and 2 6 and 25 8.90 - 1.20 0.268 4 4
6 Adults 1 and 2 6 and 25 8.90 - 1.21 0.420 4
Holcombe
2017 [36]
2 Adults 1 13 9.01 - 0.74 0.426 4 4
Tirelli 2017
[37]
3 Children 1 13 9.56 - 1.37 0.347 4
Hey 2018 [38] 1 Adults 1 29 9.90 - 0.34 0.221 4
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even within an RCT where a comparator non-
intervention group was part of the study pro-
tocol. Several of the included studies reported
change in laboratory-measured HbA1c for mul-
tiple timed end points. For our overall analysis
(Figs. 3 and 4) we have included a single end
point for each study reflecting the observed
change in HbA1c at either 2, 3 or 4 months. For
longitudinal analysis in adult subjects (Fig. 5),
all relevant timed end points up to 12 months
were included.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Statistical Analysis
Meta-analysis of change in HbA1c was per-
formed using a random effects model. Analysis
used trial-level data, weighting with the inverse
of the within-trial variance. Cochran’s hetero-
geneity statistic (Q) and the I2 statistic were
calculated [40]. Random effects meta-regression
of change in HbA1c was performed versus initial
HbA1c [41]. These are established analytical
protocols for meta-analysis of observational
data, with known limitations (Fig. 2). A single
time point from each study at 2–4 months was
used in the main analyses. Comparisons of
change in HbA1c in adults between T1D and
T2D and time in months since commencing the
FreeStyle Libre system were analysed using a
random effects meta-regression, with initial
HbA1c, type of diabetes and month considered
as fixed effects [42]. Longitudinal analysis from
baseline to 12 months included longest follow-
up and multiple interim time points from each
trial on adult subjects, where available, in order
to model temporal effects. Analysis was per-
formed using SAS version 9.4.
Trials are weighted with the inverse of the
within-trial variance, i.e. for trials with the same
variation between patients, larger trials have
more weight but for trials of the same size those
with less variation between patients have more
weight.
RESULTS
A forest plot for the overall mean change in
HbA1c across study subjects at 2–4 months
using the random effects model is shown in
Fig. 3a. The areas of the red squares are pro-
portional to the weight of the trial. The
Table 1 continued
Study Outcome
time
points
(month)
Adults/
children
Type of
diabetes
Number
of
subjects
Initial
HbA1c
(%)
Change
in
HbA1c
(%)
SE
change
in
HbA1c
(%)
Data used
in analysis
in Figs. 3
and 4
Data
used in
analysis
in Fig. 5
Mitchell 2018
[39]
3 Adults 1 13 10.28 - 0.88 0.170 4 4
A total of 29 studies were identified reporting longitudinal HbA1c data in a total of 2396 participants with T1D or T2D
using the FreeStyle Libre flash glucose monitoring system. Of these studies, 25 reported longitudinal HbA1c data over
1–12 months in a total of 1723 participants with T1D or T2D using the FreeStyle Libre flash glucose monitoring system.
This subset were used in the analysis reported, as identified in the final two columns. The four studies not used in the
reported analysis were excluded on the following basis: no initial mean HbA1c was reported [14]; no outcome timings were
reported for mean change in HbA1c [21, 32]; 12-month outcomes in children only were reported as the study end point
[19]
*Mixture of type 1 and type 2, split not reported
Mixture of type 1 (n = 6) and type 2 (n = 25)
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included 21 studies are listed in order of mean
baseline HbA1c with the highest at the bottom.
Across all study subjects (n = 1470) the FreeStyle
Libre system reduces HbA1c at 2–4 months with
an overall mean change in HbA1c of - 0.55%
(95% CI - 0.70, - 0.39). As expected, there was
a substantial degree of heterogeneity between
trials [I2 = 94.1%, s2 = 0.09, Q = 337.7
(p\ 0.0001)]. Mean HbA1c change for adult
subjects (n = 1023, Fig. 3b) across the included
studies was - 0.56% (95% CI - 0.76, - 0.36),
with heterogeneity I2= 93.3%: s2= 0.08,
Q = 164.0 (p\ 0.0001). For children (n = 447,
Fig. 3c) mean change in HbA1c was - 0.54%
(95% CI - 0.84, - 0.23). Heterogeneity was
I2= 93.9%: s2= 0.11, Q = 130.3 (p\0.0001).
The overall mean change in HbA1c with the
FreeStyle Libre system as a function of initial
HbA1c is shown in the bubble chart in Fig. 4 for
the 21 studies with 2–4-month outcomes, where
mean initial HbA1c was available. The area of
each bubble represents the weight of the trial
and the regression line from meta-regression
random effects model is displayed. On average,
for each percentage increase in mean initial
HbA1c, the mean change in final HbA1c falls by
0.31% (95% CI - 0.43 to - 0.19). For example,
this analysis indicates that if the mean initial
HbA1c is 8.5%, the expected mean reduction in
HbA1c is 0.60%, a final HbA1c of 7.90%. The
mean initial HbA1c explains a considerable
proportion of the heterogeneity between
studies in change in HbA1c, with I2 reducing
from 94.1% to 66.2%. When analysed sepa-
rately, the slopes were - 0.30 (95% CI - 0.44 to
- 0.17) and - 0.33 (95% CI - 0.73 to 0.06) for
adults and children respectively (data not
shown).
Longitudinal outcomes from baseline to
12 months across all studies on 1276 adult
subjects are shown in Fig. 5, which includes
multiple longitudinal time points within indi-
vidual studies where available. Importantly, this
analysis shows that reductions in mean HbA1c
with flash glucose monitoring appear to be
sustained. HbA1c falls within the first 2 months,
after which the reduction is steady to
12 months. The reduction in HbA1c is statisti-
cally significant from 2 months onwards. Data
from 12 months (five trials) show a reduction in
HbA1c that was similar to 9 months (two trials),
6 months (seven trials) and 3 months (eight
trials). No significant differences were detected
between adults with T1D (n = 1049) or T2D
(n = 227) (95% CI - 0.51 to 0.17, p = 0.2883).
DISCUSSION
The outcomes from the meta-analysis reported
here confirm that using the FreeStyle Libre sys-
tem can reduce chronic exposure to hypergly-
caemia, as measured by laboratory HbA1c, by
0.55%. The changes in HbA1c reported in the
Fig. 2 Limitations of this meta-analysis
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Fig. 3 a Forest plot for change in HbA1c at 2–4 months
using random effects model. The areas of the squares are
proportional to the weight of the study. A total of 21 studies
with 2–4-month outcomes data were included in the
analysis and are shown in order of mean initial HbA1c, with
the highest at the bottom. Overall mean change in HbA1c
was - 0.55, 95% CI - 0.70, - 0.39. Heterogeneity:
s2= 0.09, Q = 337.7 (p\ 0.0001), I2= 94.1%. b Forest
plot for change in HbA1c at 2–4 months in adult subjects
using random effects model. The areas of the squares are
proportional to the weight of the study. Twelve studies with
2–4-month outcomes data were included in the analysis. For
adults, overall mean change in HbA1c was - 0.56, 95% CI
- 0.76, - 0.36. Heterogeneity: s2= 0.08, Q = 164.0
(p\ 0.0001), I2= 93.3%. c Forest plot for change in
HbA1c at 2–4 months in children and adolescent subjects
using random effects model. The areas of the squares are
proportional to the weight of the study. Nine studies with
2–4-month outcomes data were included in the analysis. For
children and adolescents, overall mean change in HbA1c
was - 0.54, 95% CI - 0.84, - 0.23. Heterogeneity:
s2= 0.11, Q = 130.3 (p\ 0.0001), I2= 93.9%
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RCTs and real-world observational studies
included in this meta-analysis show a depen-
dency on mean initial HbA1c amongst the
study population in each case. Overall, for each
percentage increase in mean initial HbA1c, the
mean change in final HbA1c over 2–4 months
falls by 0.31%. Limitations of our meta-analysis
are that the recruitment of subjects into the
included observational studies was not stan-
dardised, only flash glucose monitoring arms
were considered and publication bias may be
present (Fig. 2). However, these data using the
Freestyle Libre system are consistent with the
findings from RCTs using traditional CGM. The
DIAMOND study on T1D [5] reported that the
change in HbA1c from baseline at 24 weeks in
subjects with an initial HbA1c C 8.5% (average
9.1%) was - 0.8% (mean adjusted difference)
whereas the change in HbA1c for subjects with
an initial HbA1c\8.5% (average 8.0%) was
- 0.4%. Similarly, our meta-analysis in adults
with T1D or T2D indicates that if the mean
initial HbA1c is 9.1% or 8.0%, the expected
mean reduction in HbA1c is 0.8% or 0.4%,
respectively. No improvement in HbA1c (zero
change) was achieved when mean initial HbA1c
were 6.6% overall, 6.6% in adults and 6.5% in
children.
An important finding from our meta-analysis
is that the reduction in mean HbA1c with the
FreeStyle Libre system was rapid in onset (sig-
nificant from 2 months onwards) and sustained
(Fig. 5). No significant differences were detected
between T1D and T2D. However, the majority
of subjects across the studies in this meta-anal-
ysis were adults with T1D, which limits the
ability to detect differences between T1D and
T2D. We were not able to present the longitu-
dinal pattern in children because of the limited
number of trials reporting multiple time points
(two trials) that would, to a large extent, char-
acterise the changes between months.
Fig. 4 Bubble chart of mean change in HbA1c at
2–4 months versus mean initial HbA1c. The area of each
bubble represents the weight of the study. The regression
line from meta-regression random effects model is
displayed for 21 studies with 2–4-month outcomes data.
Slope = - 0.31 (SE = 0.056, 95% CI - 0.43 to - 0.19).
Mean initial HbA1c explains a considerable proportion of
the heterogeneity between trials in change in HbA1c.
Homogeneity: s2= 0.02, Q = 56.2 (p\ 0.0001),
I2= 66.2%. On average, for each percentage increase in
mean initial HbA1c, the mean change in final HbA1c
drops by 0.31%, 95% CI - 0.43 to - 0.19. For example,
this analysis indicates that if the mean initial HbA1c is
8.5%, the expected mean reduction in HbA1c is 0.6%, a
final HbA1c of 7.9%
Fig. 5 Mean change in HbA1c with flash glucose mon-
itoring is sustained over 12 months in adult subjects.
HbA1c is significantly reduced from 2 months onwards in
adult subjects. No significant differences were detected
between type 1 and type 2 diabetes (95% CI - 0.51 to
0.17, p = 0.2883). HbA1c level reduces each month to
approximately 2 months, after which the reduction is
maintained to 12 months
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The substantial heterogeneity apparent
between the studies analysed here (I2 = 94.1%)
was expected and reflects the differences in
study design and recruitment, the length of
each study and the mean HbA1c prior to start-
ing the FreeStyle Libre system. A random effects
model was used to allow for this heterogeneity,
as is accepted for such an analysis. This
heterogeneity is a limitation of the meta-anal-
ysis as undertaken here and is an acknowledged
limitation of observational studies in general
[12, 13]. However, we have identified that ini-
tial HbA1c is a significant contributor to the
observed heterogeneity. By accounting for this
through the regression analysis of overall mean
change in HbA1c over 2–4 months with the
FreeStyle Libre system as a function of initial
HbA1c, we can report a much reduced hetero-
geneity (I2 = 66.2%), which is considered to be
moderate and acceptable within the context of
a meta-analysis. While acknowledging the lim-
itations of using real-world observational data
(Fig. 2), this meta-analysis supports the conclu-
sion that there was a consistent improvement in
HbA1c from baseline that was dependent on the
initial HbA1c.
The impact of rapid treatment decisions on
patient health and wellbeing means that the
value of new treatment modalities must be
confirmed in a timely fashion. In this context,
the increasing importance of observational
studies within meta-analyses is recognised
[12, 13]. A key aspect of guidance on inclusion
of observational studies with inherent hetero-
geneity is the obligation to consider alternative
hypotheses for the treatment effect proposed.
Because 19 of the 21 studies reported in Fig. 3
are interpreted to be prospective in design, the
most obvious alternative explanation of the
consistent reduction in HbA1c seen across the
studies reported here is a study effect in which,
because the subjects are aware of their inclusion
in the study, this has then prompted a signifi-
cant change in self-care, independent of the
capabilities of the FreeStyle Libre technology
itself. However, we argue against this for several
reasons. Firstly, across the studies included, no
evidence of specific changes in standard self-
care were reported that might result in
improved HbA1c. Rather, where noted, SMBG
testing frequencies decreased [9–11, 17, 29].
Secondly, the longitudinal analysis on adult
subjects (Fig. 5) shows that the reduction in
HbA1c is sustained over 12 months, which is
less likely to be a study effect. Lastly, the Free-
Style Libre system when used as indicated is not
a passive intervention. It provides users with a
series of active glycaemic measures at the point
of scanning, along with summary reports on
recent glucose performance. Only if blinded to
this information could a study effect truly hold
sway.
Despite its importance, HbA1c is only one
metric of glycaemic health. The FreeStyle Libre
system has already been shown to reduce the
amount of time that adults with T1D or T2D on
insulin spend with glucose in the hypogly-
caemic zone below 3.9 mmol/L (70 mg/dL)
[10, 11], with significant improvements both in
daytime and nocturnal hypoglycaemia. Simi-
larly, adults, children and adolescents with T1D
see reductions in measures of glycaemic vari-
ability with the FreeStyle Libre system, as do
adults with T2D on insulin [9–11].
CONCLUSIONS
The meta-analysis of 25 real-world observa-
tional studies and RCTs reported here confirms
that starting the FreeStyle Libre flash glucose
monitoring system as part of daily diabetes care
results in a significant reduction in HbA1c for
adults and children with T1D and for adults
with T2D. A longitudinal analysis of the data for
adult subjects with T1D or T2D showed that
using the FreeStyle Libre system results in a
rapid and sustained reduction in HbA1c. The
degree of change in HbA1c is predicted by the
HbA1c at baseline, such that study subjects with
a higher initial HbA1c achieved, on average, a
greater reduction in HbA1c over the interven-
tion period. The reductions in laboratory HbA1c
reported here for the FreeStyle Libre flash glu-
cose monitoring system are comparable to those
previously reported for other CGM devices. The
inclusion of real-world observational data
within any meta-analysis and potential publi-
cation bias are acknowledged limitations of this
analysis [12]. However, together with previously
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published RCT data for the FreeStyle Libre sys-
tem, this meta-analysis confirms that flash glu-
cose monitoring technology has a positive
impact on glucose control, limiting glucose
variability, reducing hypoglycaemia and
improving long-term glucose control as mea-
sured by HbA1c.
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